These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30064701)

  • 1. Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration.
    Mahjabeen S; Hatipoglu MK; Benbrook DM; Kosanke SD; Garcia-Contreras D; Garcia-Contreras L
    Eur J Pharm Biopharm; 2018 Sep; 130():272-280. PubMed ID: 30064701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice.
    Mahjabeen S; Hatipoglu MK; Benbrook DM; Garcia-Contreras L
    J Pharm Sci; 2018 Dec; 107(12):3179-3186. PubMed ID: 30196041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia.
    Mahjabeen S; Hatipoglu MK; Chandra V; Benbrook DM; Garcia-Contreras L
    J Pharm Sci; 2018 Feb; 107(2):638-646. PubMed ID: 28989018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile.
    Mahjabeen S; Hatipoglu MK; Kosanke SD; Garcia-Contreras D; Benbrook DM; Garcia-Contreras L
    J Pharm Sci; 2020 Jun; 109(6):2000-2008. PubMed ID: 32113976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
    Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.
    Sharma A; Benbrook DM; Woo S
    PLoS One; 2018; 13(4):e0194046. PubMed ID: 29634717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.
    Sharma A; Li M; Thavathiru E; Ibrahim M; Garcia-Contreras L; Benbrook DM; Woo S
    AAPS J; 2020 Feb; 22(2):51. PubMed ID: 32086622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.
    Benbrook DM; Janakiram NB; Chandra V; Pathuri G; Madka V; Stratton NC; Masamha CP; Farnsworth CN; Garcia-Contreras L; Hatipoglu MK; Lighfoot S; Rao CV
    Invest New Drugs; 2018 Aug; 36(4):561-570. PubMed ID: 29273857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryogenic Fabrication of Dry Powders to Enhance the Solubility of a Promising Anticancer Drug, SHetA2, for Oral Administration.
    Ibrahim M; Hatipoglu MK; Garcia-Contreras L
    AAPS PharmSciTech; 2019 Jan; 20(1):20. PubMed ID: 30604109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs.
    Kabirov KK; Kapetanovic IM; Benbrook DM; Dinger N; Mankovskaya I; Zakharov A; Detrisac C; Pereira M; Martín-Jiménez T; Onua E; Banerjee A; van Breemen RB; Nikolić D; Chen L; Lyubimov AV
    Drug Chem Toxicol; 2013 Jul; 36(3):284-95. PubMed ID: 22947079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing.
    Sharma A; Liu X; Chandra V; Rai R; Benbrook DM; Woo S
    AAPS J; 2023 Dec; 26(1):5. PubMed ID: 38087107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of flexible-heteroarotinoids for kidney cancer.
    Liu T; Masamha CP; Chengedza S; Berlin KD; Lightfoot S; He F; Benbrook DM
    Mol Cancer Ther; 2009 May; 8(5):1227-38. PubMed ID: 19417155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a reverse phase HPLC method for SHetA2, a novel anti-cancer drug, in mouse biological samples.
    Kukut Hatipoglu M; Mahjabeen S; Garcia-Contreras L
    J Pharm Biomed Anal; 2019 Jun; 170():124-131. PubMed ID: 30921646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.
    Myers T; Chengedza S; Lightfoot S; Pan Y; Dedmond D; Cole L; Tang Y; Benbrook DM
    Invest New Drugs; 2009 Aug; 27(4):304-18. PubMed ID: 18802666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHetA2 Dry Powder Aerosols for Tuberculosis: Formulation, Design, and Optimization Using Quality by Design.
    Ibrahim M; Hatipoglu MK; Garcia-Contreras L
    Mol Pharm; 2018 Jan; 15(1):300-313. PubMed ID: 29219321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.
    Masamha CP; Benbrook DM
    Cancer Res; 2009 Aug; 69(16):6565-72. PubMed ID: 19638577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.
    Zhou T; Hu M; Pearlman A; Rohan LC
    Biochem Pharmacol; 2016 Sep; 116():162-75. PubMed ID: 27453435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.
    Benbrook DM; Guruswamy S; Wang Y; Sun Z; Mohammed A; Zhang Y; Li Q; Rao CV
    Cancer Prev Res (Phila); 2013 Sep; 6(9):908-16. PubMed ID: 23852423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
    Lin YD; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun SY
    Cancer Res; 2008 Jul; 68(13):5335-44. PubMed ID: 18593935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of reproductive stage at PRID insertion on synchronization of estrus and ovulation in mares.
    Handler J; Schönlieb S; Hoppen HO; Aurich C
    Anim Reprod Sci; 2007 Feb; 97(3-4):382-93. PubMed ID: 16616441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.